Sign in

    Danis

    Director and Senior Analyst at Citizens CM

    Danis is a Director and Senior Analyst at Citizens Capital Markets, specializing in equity research coverage of public companies in the financial services and fintech sectors. He has covered firms such as JPMorgan Chase, Bank of America, and Square, with a performance record that includes a 65% success rate and average annualized returns of over 8% on his stock recommendations according to independent analyst ranking platforms. Danis began his professional career at Deloitte in 2011, later holding positions at Jefferies and Sandler O’Neill before joining Citizens CM in 2018, where he expanded his focus to include emerging fintech innovators. He is FINRA Series 7, 63, and 86/87 certified, underscoring his commitment to regulatory compliance and professional standards in the finance industry.

    Danis's questions to AVANOS MEDICAL (AVNS) leadership

    Danis's questions to AVANOS MEDICAL (AVNS) leadership • Q4 2024

    Question

    Danis from Citizens CM asked for more detail on the 2025 guidance, seeking to understand the key drivers for the high and low ends of the range. He also inquired about the free cash flow outlook for 2025 and the primary focus for M&A transactions. Finally, he requested a reminder on the product innovations planned for the upcoming year, including their nature and timing.

    Answer

    Interim CEO Michael Greiner detailed that guidance upside could come from tariff certainty, favorable FX, extended competitor backorders, or strong product launches, while downside risk is mainly macroeconomic. He projected 2025 free cash flow to be similar to 2024's normalized results, excluding a one-time tax receivable. Greiner stated that M&A will focus on the 'Specialty Nutrition Systems' ecosystem. He also noted that near-term product innovations are concentrated in this segment, with several launches planned for late 2025 to defend their market-leading position.

    Ask Fintool Equity Research AI